{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:34:21Z","timestamp":1793284461894,"version":"4.5.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["23-A-16"],"award-info":[{"award-number":["23-A-16"]}]},{"name":"National Cancer Center Research and Development Fund","award":["23-A-17"],"award-info":[{"award-number":["23-A-17"]}]},{"name":"National Cancer Center Research and Development Fund","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2026-J-03"],"award-info":[{"award-number":["2026-J-03"]}]},{"name":"Grants-in-Aid for Cancer Research","award":["20S-1"],"award-info":[{"award-number":["20S-1"]}],"id":[{"id":"https:\/\/ror.org\/01yv62k92","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Grants-in-Aid for Cancer Research","award":["20S-6"],"award-info":[{"award-number":["20S-6"]}],"id":[{"id":"https:\/\/ror.org\/01yv62k92","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Grants-in-Aid for Cancer Research","award":["23-A-16"],"award-info":[{"award-number":["23-A-16"]}],"id":[{"id":"https:\/\/ror.org\/01yv62k92","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Grants-in-Aid for Cancer Research","award":["23-A-17"],"award-info":[{"award-number":["23-A-17"]}],"id":[{"id":"https:\/\/ror.org\/01yv62k92","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health and Labour Sciences Research Grants for Clinical Cancer Research","award":["19-20"],"award-info":[{"award-number":["19-20"]}]},{"name":"Health and Labour Sciences Research Grants for Clinical Cancer Research","award":["22-14"],"award-info":[{"award-number":["22-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12185-026-04292-1","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:31:39Z","timestamp":1790519499000},"page":"624-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7730-2531","authenticated-orcid":false,"given":"Shinya","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"issue":"10","key":"4292_CR1","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3390\/vaccines10101644","volume":"10","author":"SMF Akbar","year":"2022","unstructured":"Akbar SMF, Mahtab MA, Khan S, Yoshida O, Hiasa Y. Development of therapeutic vaccine for chronic hepatitis B: concept, cellular and molecular events, design, limitation, and future projection. Vaccines (Basel). 2022;10(10):1644. https:\/\/doi.org\/10.3390\/vaccines10101644.","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"4292_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00432-012-1279-y","volume":"138","author":"N Becker","year":"2012","unstructured":"Becker N, Schnitzler P, Boffetta P, Brennan P, Foretova L, Maynadi\u00e9 M, et al. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case\u2013control study Epilymph. J Cancer Res Clin Oncol. 2012;138(12):1993\u20132001. https:\/\/doi.org\/10.1007\/s00432-012-1279-y.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4292_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1324113","author":"Z Zhan","year":"2024","unstructured":"Zhan Z, Guo W, Wan X, Wang B, Li J, Wang H, et al. Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1324113.","journal-title":"Front Immunol"},{"issue":"5","key":"4292_CR4","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1111\/cas.14846","volume":"112","author":"N Yamauchi","year":"2021","unstructured":"Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, et al. Prophylactic antiviral therapy for hepatitis B virus surface antigen\u2010positive patients with diffuse large B\u2010cell lymphoma treated with rituximab\u2010containing chemotherapy. Cancer Sci. 2021;112(5):1943\u201354. https:\/\/doi.org\/10.1111\/cas.14846.","journal-title":"Cancer Sci"},{"issue":"1","key":"4292_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/bloodadvances.2021005316","volume":"6","author":"C Fern\u00e1ndez-Rodr\u00edguez","year":"2022","unstructured":"Fern\u00e1ndez-Rodr\u00edguez C, Rodr\u00edguez-Sevilla JJ, Fern\u00e1ndez-Ibarrondo L, S\u00e1nchez-Gonz\u00e1lez B, Gibert J, Bento L, et al. Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. Blood Adv. 2022;6(1):82\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2021005316.","journal-title":"Blood Adv"},{"issue":"4","key":"4292_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/bloodadvances.2020002567","volume":"5","author":"K Ohmachi","year":"2021","unstructured":"Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, et al. A randomized phase 2\/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Adv. 2021;5(4):984\u201393. https:\/\/doi.org\/10.1182\/bloodadvances.2020002567.","journal-title":"Blood Adv"},{"key":"4292_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03170-24","author":"Y Rong","year":"2025","unstructured":"Rong Y, Wang M, Ma Y, Liang Y, Ye L, Guo L, et al. Serum hepatitis B core antibody as the prognostic factor for diffuse large B-cell lymphoma. Microbiol Spectr. 2025. https:\/\/doi.org\/10.1128\/spectrum.03170-24.","journal-title":"Microbiol Spectr"},{"issue":"5","key":"4292_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61(5):719\u201329. https:\/\/doi.org\/10.1093\/cid\/civ344.","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04292-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:53:04Z","timestamp":1793281984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04292-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4292"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04292-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shigeru Kusumoto: advisory roles for Eli Lilly, Chugai Pharmaceutical, Kyowa Kirin, Genmab, and Janssen; research funding from Daiichi Sankyo, Chugai Pharmaceutical, Ono Pharmaceutical, Janssen, Genmab, Meiji Seika Pharma, Bristol Myers Squibb, Takeda, AbbVie, MSD, and BeOne Medicines; honoraria from Chugai Pharmaceutical, Daiichi Sankyo, Janssen, Ono Pharmaceutical, Eisai, Meiji Seika Pharma, AbbVie, Nippon Shinyaku, Astellas Pharma, Novartis, Zenyaku Kogyo, Fujimoto Pharmaceutical, SymBio Pharmaceuticals, Eli Lilly, Genmab, Sanofi, Takeda, Sumitomo Pharma, Mundipharma, AstraZeneca, MSD, BeOne Medicines, and Gilead. Ken Ohmachi: honoraria from Chugai Pharmaceutical, AbbVie, and Genmab. Junya Makiyama: consulting fees from Daiichi Sankyo and Janssen; honoraria from AbbVie GK, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Genmab, Janssen, Kyowa Kirin, Meiji Seika Pharma, Minophagen, Nippon Shinyaku, Ono Pharmaceutical, Sanofi, and Takeda; travel support from Takeda. Tomohiro Kinoshita: employee of the Japanese Red Cross Society; no competing interests. Wataru Munakata: research funding from Chugai Pharmaceutical, Genmab, Nippon Shinyaku, and Ono Pharmaceutical; honoraria from Chugai Pharmaceutical, Ono Pharmaceutical, Takeda, Nippon Shinyaku, and AstraZeneca. Dai Maruyama: honoraria from Ono Pharmaceutical, Nippon Shinyaku, Janssen, Eisai, Chugai Pharmaceutical, Roche, Kyowa Kirin, MSD, Sanofi, SymBio Pharmaceuticals, Takeda, AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, Novartis, and BeOne Medicines; research funding from Ono Pharmaceutical, Janssen, Eisai, Chugai Pharmaceutical, Kyowa Kirin, MSD, Sanofi, SymBio Pharmaceuticals, Takeda, AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, Novartis, Otsuka, Pfizer, Astellas Pharma, BeOne Medicines, Eli Lilly, Daiichi Sankyo, and Meiji Seika Pharma. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JCOG0601 was conducted in accordance with the Declaration of Helsinki, the ethical guideline for clinical research issued by the Ministry of Health, Labour and Welfare in Japan, and the Clinical Trials Act in Japan. The study protocol of JCOG0601 has been approved by the Protocol Review Committee of Japan Clinical Oncology Group (JCOG) and the institutional review boards of each participating center and the National Cancer Center Hospital Certified Review Board in Tokyo, Japan.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}